Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $1,330,813 | $1,700,088 | $230,064 | $1,241,201 |
| Dep. & Amort. | $0 | $0 | $5,670 | $22,996 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $2,344 | $2,357 | $2,170 | $2,443 |
| Change in WC | $53,383 | $5,382 | $32,662 | -$16,322 |
| Other Non-Cash | $1,382,446 | $1,279,975 | $1,873,414 | $767,218 |
| Operating Cash Flow | $2,768,986 | $2,987,802 | $2,143,980 | $2,017,536 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | $0 |
| Net Acquisitions | -$10,955 | -$12,542 | -$9,896 | -$34,855 |
| Inv. Purchases | -$2,736,201 | -$2,115,522 | -$2,565,068 | -$3,593,656 |
| Inv. Sales/Matur. | $118,361 | $25,831 | $1,545,543 | $1,776,308 |
| Other Inv. Act. | -$49,320 | $29,444 | $0 | -$18,077 |
| Investing Cash Flow | -$2,678,115 | -$2,072,789 | -$1,029,421 | -$1,870,280 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $1,471,235 | -$1,000,000 | $0 | $1,272,533 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$229,651 | -$304,759 | $0 | $0 |
| Dividends Paid | -$376,465 | -$358,327 | -$333,322 | -$285,184 |
| Other Fin. Act. | -$503,974 | -$485,668 | -$611,534 | -$602,237 |
| Financing Cash Flow | $361,145 | -$2,148,754 | -$944,856 | $385,112 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $452,016 | -$1,233,741 | $169,703 | $532,368 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $477,010 | $1,710,751 | $1,541,048 | $1,008,680 |
| End Cash | $929,026 | $477,010 | $1,710,751 | $1,541,048 |
| Free Cash Flow | $2,768,986 | $2,987,802 | $2,143,980 | $2,017,536 |